Actively Recruiting
Safety Study of Inavolisib with Fulvestrant and Optional Palbociclib in Adults with PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes
Led by Hoffmann-La Roche · Updated on 2026-10-20
40
Participants Needed
10
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety of combining inavolisib and fulvestrant, with or without palbociclib, in adults who have PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer and type 2 diabetes. The study focuses on monitoring adverse effects, especially those related to blood sugar levels, in participants receiving this treatment combination. Participants will receive oral inavolisib on days 2 to 28 of each 28-day cycle. Intramuscular fulvestrant is given on days 1 and 15 during the first cycle, then on day 1 of each following cycle. Some participants will also take oral palbociclib on days 1 to 21 of each cycle. This is an open-label, single-group phase II study with treatment continuing up to approximately 21 months. During the study, participants will be regularly assessed for adverse events including severe hyperglycemia and hospitalizations related to high blood sugar. Researchers will also monitor treatment side effects, response rates, disease progression, overall survival, and quality of life using questionnaires and clinical evaluations. Laboratory tests and performance status will be checked to ensure safety, with the study lasting up to about 21 months per participant.
CONDITIONS
Brief Title
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Research Team
R
Reference Study ID Number: GO45322 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here